Table of Content

1. Introduction to Global Trispecific Cancer Antibody Drug Market
1.1 Trispecific Cancer Antibody Mechanism of Action Against Cancer Cells
1.2 History of the Development of Trispecific Cancer Antibody Drug Development


2. Cancer Cases Engaging More Potential Trispecific Cancer Research Studies at Clinical Level
2.1 Trispecific Cancer Antibody Drug Therapy Market Beneficial for all Cancer Types
2.2 Potential Trispecific Cancer Antibody Therapy for Non-Small Cell Lung Cancer
2.3 Potential Trispecific Cancer Antibody Drug Therapy for the Treatment of Breast
Cancer
2.4 Potential Trispecific Cancer Antibody Therapy Market for Prostate Cancer
2.5 Potential Trispecific Cancer Antibody Therapy Market for Rest of the Cancer
Types
2.6 Trispecific Cancer Antibody Drug Immunotherapy Market as a Saviour for
Increasing Prevalence of Cancer Cases
2.7 Trispecific Antibody Immunotherapy Market Clinical Experience


3. Clinical Insights for Current Trispecific Cancer Antibody Drug Therapy Market
3.1 Importance of Clinical Research Studies for the Overall Development of
Trispecific Cancer Antibody Drug Therapy Market
3.2 Research Clinical Insights for Trispecific Cancer Antibody Drug Therapy against
Multiple Myeloma


4. Trispecific Cancer Antibody Drug Therapy Market Overcoming the Challenges for Monoclonal Antibody & Bispecific Antibody Drug Market
4.1 Trispecific Cancer Antibody Drug Therapy Market an Enhanced Version of
Monoclonal Antibody Therapy Market
4.1.1 Trispecific Cancer Antibody Drug Therapy Vs. General Monoclonal Antibody
Drug Class
4.1.2 Construction Benefits of Using Trispecific Cancer Antibody Drug Therapy Over
Monoclonal Antibodies
4.2 Trispecific Cancer Antibody Drug Therapy in Overcoming Bispecific Cancer
Antibody Drug Therapy Challenges


5. Tri-Specific Natural Killer Cell Nanoengagers to Address Cancer Therapeutic Indication


6. Forging Novel Pathways for Improving Research & Development Sector for Cancer by Trispecific Cancer Antibody Therapy
6.1 Trispecific Cancer Antibody Drug Therapy Market Research & Development Sector
Promoting Current Cancer Therapy Market
6.2 Novel Trispecific Cancer Antibody Therapy Drugs to Boost Chemotherapy Cancer
Market
6.3 Novel Trispecific Cancer Antibody Drug Market Boosting the Future Radiation
Therapy Market
6.4 Novel Trispecific Cancer Antibody Drug Market Boosting Other Available Cancer
Therapies Market


7. Global Market Implications for Ongoing Research Studies & Collaborations for Trispecific Cancer Antibody Drug Market
7.1 Numab & Vasella Therapeutics to Collaborate for PD-L1x4-1BBxHSA Trispecific
ND021 Candidate in the Cancer Patients
7.2 GTB-3550 Trispecific Recombinant Fusion Protein Development by GT Biopharma
7.3 Sanofi to Target Bi-specifcic & Multi-Specific Antibodies for Overall Development
of Cancer Pharmaceutical Industry
7.4 Sunshine Pharmaceuticals & Numab Therapeutics to Undergo Partnership for the
Development of Multi-Specific Cancer Antibody Drugs for Cancer Patients
7.5 SAR 441236 Trispecific Cancer Antibody Drug Development by Brigham Health
Hospital
7.6 Numab Therapeutics Evaluation of NM21-1480 Trispecific Cancer Antibody in the
Solid Cancer Patients


8. Global Trispecific Antibodies Clinical Pipeline Overview
8.1 By Country
8.2 By Indication
8.3 By Organization
8.4 By Patient Segment


9. Global Trispecific Antibodies Pipeline Clinical Insight By Company, Indication & Phase
9.1 Reserach
9.2 Preclinical
9.3 Phase-I
9.4 Phase-I/II


10. Insight for Driving Factors & Challenges for the Trispecific Cancer Antibody Drug Market
10.1 Driving Parameters for Trispecific Cancer Antibody Drug Market
10.2 Challenge Observed for the Current Trispecific Cancer Antibody Drug Therapy
Market


11. Future Directions for Trispecific Cancer Antibody Drug Therapy Market at Global Level


12. Competitive Landscape
12.1 AbbVie
12.2 Affimed
12.3 Biotheus
12.4 Harpoon Therapeutics
12.5 Macrogenics
12.6 Numab
12.7 Sanofi
12.8 Sichuan Baili Pharmaceuticals



List of Figures


Figure 2-1: Global – Most Diagnosed Cancer Types (Million)
Figure 2-2: Trispecific Cancer Antibody Therapy for Variety of Cancer Types
Figure 2-3: Arrival of Trispecific Cancer Antibody Market into the Cancer Therapy Market
Figure 3-1: Targets Selected for Testing Tr-Specific Cancer Antibody Therapy on Multiple Myeloma
Figure 4-1: Hybridoma Technology for the Production of Monoclonal Antibody
Figure 4-2: Monoclonal Antibody Mechanism of Action against Cancer Cells
Figure 4-3: Applications of Trispecific Killer Engagers
Figure 4-4: Trispecific Cancer Antibody Drug Therapy Vs. General Monoclonal Antibodies
Figure 4-5: Applications of Specialized Trispecific Cancer Antibody Drug Therapy Constructs Over Monoclonal Antibody Drug Therapy Construction
Figure 8-1: Global - Trispecific Antibodies Clinical Pipeline by Country (Number of Drugs), 2020 till 2024
Figure 8-2: Global - Trispecific Antibodies Clinical Pipeline by Indication (Number of Drugs), 2020 till 2024
Figure 8-3: Global - Trispecific Antibodies Clinical Pipeline by Organization (Number of Drugs), 2020 till 2024
Figure 8-4: Global - Trispecific Antibodies Clinical Pipeline by Indication (Number of Drugs), 2020 till 2024
Figure 9-1: Global - Number of Trispecific Antibodies in Clinical Pipeline by Phase (%), 2020 till 2024
Figure 9-2: Global - Trispecific Antibodies in Clinical Pipeline by Phase (Number of Drugs), 2020 till 2024
Figure 9-3: Global - Trispecific Antibodies Clinical Pipeline by Phase (Number of Trials), 2020 till 2024
Figure 10-1: Global – Drivers for Trispecific Cancer Antibody Drug Therapy Market
Figure 11-1: Global – Future Drivers for Trispecific Cancer Antibody Drug Therapy Market